Cost-Effectiveness Analysis of Dacomitinib versus Gefitinib in the First-Line Treatment of EGFR-Positive Advanced or Metastatic Non-Small Cell Lung Cancer
Longfeng Zhang,1 Na Li,2 Maobai Liu,2 Bin Zheng,2 Zhijuan Wu,3 Hongfu Cai2 1Department of Thoracic Oncology, Fujian Provincial Cancer Hospital, Fujian Medical University Cancer Hospital, Fuzhou, Fujian Province, People’s Republic of China; 2Department of Pharmacy, Fujian Medical University...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2021-05-01
|
| Series: | Cancer Management and Research |
| Subjects: | |
| Online Access: | https://www.dovepress.com/cost-effectiveness-analysis-of-dacomitinib-versus-gefitinib-in-the-fir-peer-reviewed-fulltext-article-CMAR |